OBJECTIVES The goal of this study was to compare survival between transcatheter mitral valve (MV) repair using MitraClip system (Abbott Vascular, Santa Clara, California), MV-surgery, and conservative treatment in high-surgical-risk patients symptomatic with severe mitral valve regurgitation (MR).
M itral valve (MV) regurgitation
(MR) is an important clinical condition, representing >30% of native valve diseases (1) . In the absence of surgery, patients with symptomatic MR have a poor prognosis, even with optimal medical therapy (2) . Indeed, it has been shown that medical therapy does not reduce survival and only improves symptoms of heart failure (3) . Therefore, the guidelines recommend surgical treatment with a class I (4, 5) . Despite this clear statement, Euro Heart Survey on valve disease indicates that up to 50% of these patients are not referred for surgery due to high peri-and postoperative risk, mainly driven by advanced age, depressed left ventricular (LV) function, and other comorbidities (6) . Higher percentages of rejections have been reported recently, when MR was accompanied by heart failure (7) . The reported in-hospital mortality rate in these high-surgical-risk patients is estimated to be up to 25% (8, 9) . New transcatheter techniques may introduce an alternative to surgery in highsurgical-risk patients. In the past few years, most evidence on transcatheter MV repair has accumulated for transcatheter edge-to-edge MV repair using the MitraClip system (Abbott Vascular, Santa Clara, California) (10) (11) (12) (13) (14) (15) (16) . Mimicking the surgical procedure introduced by Alfieri et al. (17) , this technique creates a double MV orifice by means of a clip in the midportion of the 2 leaflets. Previous studies, also from our group, proved the MitraClip system's feasibility and efficacy in high-surgical-risk patients (10, (13) (14) (15) (16) . No data are available comparing outcomes of transcatheter MV repair with surgery and conservative treatment in high-surgical-risk patients. In this study, we aimed to compare survival outcomes in these different treatment strategies in high-surgical-risk patients with symptomatic MR. PROCEDURE. All procedures were performed as previously described (14, 19, 20) . In brief, the clip device system is delivered to the left atrium via a transseptal puncture, advanced into the left ventricle, and then Swaans et al. STATISTICAL ANALYSIS. Data are given as mean AE SD in the text and in Table 1 . The dichotomous variables were tested by the chi-square test. Comparisons between groups were done by analysis of variance, with the least significant difference test as a post-hoc test.
METHODS
To reduce confounding factors due to imbalances in baseline characteristics, propensity scores were used to weight samples from the transcatheter MV repair, surgery, and control groups so that the distributions of observed baseline characteristics were more comparable across the 3 groups. We computed propensity scores by means of generalized boosted modeling, a machine learning technique that relies on tree-based regression models that are built in an iterative fashion with a multinomial approach trying to achieve balance among the 3 groups (24). We used Fifty-nine patients (mean age, 71.7 AE 9.6 years; 54.2% male) were treated conservatively.
Mean follow-up time was 1.7 AE 1.1, 3.8 AE 1.9, and 2.7 In total, pulmonary hypertension was more prevalent in the transcatheter MV repair group, but severe pulmonary hypertension (systolic pulmonary artery pressure >55 mm Hg) was more common in the high-risk surgery and conservatively treated group.
FIGURE 1 Kaplan-Meier Survival Curves
After 1-year follow-up, the transcatheter mitral valve (MV) repair and the high-risk surgery group had similar survival rates (85.8% vs. 85.2%, respectively), whereas only 67.7% of the patients in the conservatively treated group survived. The same trend was observed during the second and third year of follow-up. SURVIVAL OUTCOMES. After 1 year of follow-up, the transcatheter MV repair and the high-risk surgery group showed similar survival rates (85.8% vs. 85.2%, respectively), whereas only 67.7% of the patients in the conservatively treated group survived (Fig. 1) . The 2-and 3-year survival rates in the conservatively treated group were 52.5% and 45.8%, respectively.
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The survival rates for the transcatheter MV repair group (75.5% and 62.3% after 2 and 3 years, respectively) and high-risk surgery group (77.8% and 68.5% after 2 and 3 years, respectively) were comparable.
During follow-up, there were 29 cardiac deaths and 6 noncardiac deaths in the transcatheter MV repair group. In the high-risk surgery group, 18 cardiac deaths and 5 noncardiac deaths were reported. The "standard" treatment of MR is surgery. Logically, the patients denied for surgery must be at increased surgical risk. Indeed, it has been suggested that the patient risk factors differ significantly between surgical patients and transcatheter MV repair patients, favoring surgical patients (25) . In an era in which up to 50% of patients are denied surgery, simply because of that high risk, transcatheter MV repair would be the only alternative therapy! The landmark EVEREST II trial, in which patients at low and moderate risk were also included, showed that the survival rates were similar between transcatheter MV repair and surgery groups (12, 26) . Our report expands the EVEREST II data on high-surgical-risk patients, suggesting that transcatheter MV repair may even be as good as surgical therapy. Further improvement of the survival rates may be expected by gaining experience leading to improved durability and completeness of MV repair (27) .
Finally, there is controversy in the literature concerning surgical treatment of FMR in terms of survival
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